The use of a blood-breaking saponin A or a pharmaceutically acceptable salt thereof in a drug for treating viral eye diseases
By applying thrombolytic saponin A or its pharmaceutically acceptable salt, the problems of drug resistance and toxic side effects of existing HSV-1 treatment drugs have been solved, achieving effective treatment of HSVE, especially significantly improving the survival rate and symptom improvement in mice in the HSV-1 infection model.
Patent Information
- Application Number
- CN202511264941.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-05
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2045-09-05
AI Technical Summary
There is a lack of effective drugs for treating herpes simplex virus ophthalmopathy (HSVE), especially for HSV-1, and existing drugs such as acyclovir have problems with drug resistance and toxic side effects.
The application of bismuth subtilis saponin A or its pharmaceutically acceptable salt, via intraperitoneal injection or ophthalmic instillation, has been shown to have a highly effective inhibitory effect on HSV-1 in the treatment of herpes simplex virus ophthalmopathy, particularly ocular infections caused by HSV-1.
Blood-dissolving saponin A significantly inhibited HSV-1 infection in HSVE-susceptible cells, improved the survival rate of mice, reduced clinical symptoms caused by HSV-1 infection, and avoided the drug resistance problem caused by long-term use of acyclovir.
Smart Images

Figure CN120960241B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, specifically to the use of a blood-breaking saponin A or a pharmaceutically acceptable salt thereof in a drug for treating viral eye diseases. Background Technology
[0002] With the development of antibacterial drugs, bacterial eye diseases have been effectively controlled, while viral eye diseases have become a prominent and challenging clinical problem. Different viruses cause varying clinical manifestations and severity, affecting the eyelids, conjunctiva, cornea, retina, and uvea. Some viruses can even affect the optic nerve, leading to permanent vision loss. Among these, herpes simplex virus ophthalmopathy (HSVE) is a common and potentially blinding disease that severely impairs visual function. Approximately 90% of cases are caused by herpes simplex virus type I (HSV-1) infection. It primarily manifests as inflammation and damage to the cornea, conjunctiva, eyelids, and other ocular tissues. In severe cases, it can affect the sclera, iris, and retina, ultimately leading to visual impairment or even blindness.
[0003] Herpes simplex keratitis (HSK) caused by HSV-1 is the leading cause of infectious blindness worldwide. Its clinical characteristics include a long course, high recurrence rate, and the development of corneal herpes, corneal leukoma, corneal neovascularization, corneal ulceration, and even perforation. It is the most prevalent infectious corneal disease in the world today. Approximately 50-80% of the global population is seropositive for HSV-1 antibodies, and in some developing countries, the seropositivity rate can exceed 90%, indicating a large population base and significant potential threat of HSVE. HSV infection includes primary and recurrent infections. During initial HSV-1 infection, the virus replicates and produces progeny by directly infecting the epithelial cells of the cornea, conjunctiva, and other mucosa, and continues to infect adjacent cells. Subsequently, the virus travels from the corneal nerve to the trigeminal ganglion where it remains latent. When the body is stimulated by external factors, the virus can be reactivated, causing recurrent HSVE. HSVE recurrence is very common, and its difficulty in treatment lies mainly in its high recurrence rate. High recurrence rates lead to the accumulation and exacerbation of related symptoms, significantly increasing the risk of visual impairment and even blindness. Due to the recurrence of infection, visual impairment becomes very common. Compared to developed countries, the incidence of HSK is higher in developing countries. In my country, the prevalence of viral keratitis is approximately 0.11%, of which up to 42.5% of corneal infectious blindness cases are caused by HSV-1. In addition to the risk of visual impairment, HSVE also affects quality of life and imposes a huge economic burden. It is estimated that the global cost of HSK treatment is approximately US$17.7 million annually, indicating that HSVE has caused long-term and serious harm to human society. Developing effective treatment strategies for HSVE will greatly improve global health.
[0004] Because HSV is latent, there is currently no cure for HSVE. Treatment relies on FDA-approved nucleoside analogues such as acyclovir (ACV), but these drugs have a single target, and long-term use leads to increasing drug resistance. These drugs also have some toxic side effects, causing central nervous system disorders and irreversible kidney damage. Although research into new drugs for HSV has been ongoing, various limitations and shortcomings, such as low solubility, low bioavailability, limited drug delivery systems, and significant toxic side effects, have prevented FDA-approved treatments from being updated in the past two decades. Therefore, there is an urgent need to find and develop new drugs that effectively treat HSVE. Summary of the Invention
[0005] The purpose of this invention is to provide the application of blood-breaking saponin A or its pharmaceutically acceptable salt in a drug for treating viral eye diseases, in order to solve the problems mentioned in the background art.
[0006] To solve the above-mentioned technical problems, the present invention provides the following technical solution: the application of a blood-breaking saponin A or its pharmaceutically acceptable salt in a drug for treating viral eye diseases.
[0007] Furthermore, the viral eye disease is herpes simplex virus eye disease induced by herpes simplex virus type I.
[0008] Furthermore, the molecular formula of the blood-breaking saponin A is as follows: The structural formula is: .
[0009] Furthermore, the half-maximal effective concentration (EC50) of the blood-breaking saponin A or a pharmaceutically acceptable salt thereof against herpes simplex virus type I is... 50 The range is 5.286~8.293μM.
[0010] Furthermore, the glycoside A derived from the traditional Chinese medicine glycoside D.
[0011] Furthermore, the medication is either an injection or eye drops.
[0012] Furthermore, the injection is administered via intraperitoneal injection, and the dosage of thrombolytic saponin A or its pharmaceutically acceptable salt is 5 mg / kg.
[0013] Furthermore, the eye drops are administered via eye drops, with a dosage of 20 μl, and the concentration of blood flow interrupting saponin A or its pharmaceutically acceptable salt is 1 mg / mL.
[0014] Compared with the prior art, the beneficial effects achieved by the present invention are as follows: The present invention applies Duanxueliu saponin A or its pharmaceutically acceptable salt to a drug for the treatment of viral eye diseases. Duanxueliu saponin A is the main component of the traditional Chinese medicine Duanxueliu. It has a prominent anti-HSV-1 effect in HSVE-susceptible cells HCE (human corneal epithelial cell line) and can also effectively inhibit HSV-1 infection in other HSVE-susceptible cells. At a concentration of 10 μM, it almost completely inhibits the cytopathic effect.
[0015] Currently, the treatments for HSV-1 and HSV-2 are almost identical, primarily relying on FDA-approved nucleoside analogs such as acyclovir (ACV). However, those skilled in the art, based on past experience, often overlook the differences between the two when researching and developing related therapeutics. HSV-1 is the most prevalent virus causing herpes simplex eye disease, making the development of therapeutics against HSV-1 crucial. However, there are currently no reports on the application of cyclophosphamide A in this field, nor on its therapeutic effects in HSVE-susceptible cells or in HSVE-infected mouse models.
[0016] This invention targets the half-maximal effective concentration (EC50) of thrombolytic saponin A against HSV-1 and HSV-2 in HSVE-susceptible cells (HCE, HconEpic, and Primary corneal epithelial cells). 50 Measurements revealed that the half-maximal effective concentration (EC50) of bismuth substituent A for HSV-1 was... 50 The effective concentrations were all between 5.286 and 8.293 μM, significantly better than its inhibitory effect on HSV-2 (EC). 50 (19.54~24.73 μM); In two mouse models of HSVE induced by HSV-1 infection (ocular inoculation and nasal inoculation), Duanxue Liu saponin A effectively improved the clinical symptoms and increased the survival rate of mice. This invention breaks through existing technical biases and is conducive to promoting the application of Duanxue Liu saponin A or its pharmaceutically acceptable salts, as well as traditional Chinese medicines containing the active substance (such as Duanxue Liu), in the development of therapeutic drugs for eye diseases caused by HSV-1, effectively reducing or avoiding drug resistance problems caused by long-term use of nucleoside analogs such as acyclovir (ACV). Attached Figure Description
[0017] The accompanying drawings are provided to further illustrate the invention and form part of the specification. They are used in conjunction with embodiments of the invention to explain the invention and do not constitute a limitation thereof. In the drawings: Figure 1 This is the cytotoxicity of blood saponin A as described in Example 1 of the present invention.
[0018] Figure 2Example 2 of this invention interrupts the antiviral activity of blood saponin A and acyclovir in human corneal epithelial cell line (HCE), human conjunctival epithelial cell line (HconEpic), and mouse primary corneal epithelial cells, respectively, where A is anti-HSV-1 activity and B is anti-HSV-2 activity.
[0019] Figure 3 These are microscopic images of the cell states of the normal control group (Control), the virus infection group (HSV-1), and the blood-breaking saponin A administration group (Clin) in Example 2 of this invention.
[0020] Figure 4 This describes the survival status of mice after HSV-1 ocular inoculation with HSVE in Example 3 of the present invention.
[0021] Figure 5 This describes the weight changes in mice after HSV-1 ocular inoculation with HSVE in Example 3 of the present invention.
[0022] Figure 6 This is the scoring standard for ocular symptoms in mice after HSV-1 ocular inoculation with HSVE in Example 3 of the present invention.
[0023] Figure 7 This describes the survival status of mice after nasal inoculation with HSV-1 for HSVE in Example 4 of this invention.
[0024] Figure 8 This is the change in body weight of mice after HSV-1 intranasal inoculation with HSVE in Example 4 of the present invention.
[0025] Figure 9 This is the scoring standard for ocular symptoms in mice after HSV-1 intranasal inoculation with HSVE in Example 4 of the present invention.
[0026] Figure 10 This is the result of the determination of the anti-HSV-1 effect of 15 main components of the traditional Chinese medicine Duanxueliu in human corneal epithelial cells HCE in Example 5 of the present invention; among them, 1-luteolin, 2-apigenin, 3-isosalicylate, 4-Duanxueliu saponin A, 5-lemon balsamin, 6-naringenin, 7-rutin-naringenin, 8-apigenin-7-O-glucuronide, 9-hesperidin, 10-hesperidin, 11-gallic acid, 12-quercetin, 13-safflower glycoside, 14-saikosaponin, and 15-rosmarinic acid. Detailed Implementation
[0027] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0028] Materials used in this invention and their sources: Clin saponin A was purchased from Beijing Solarbio Biotechnology Co., Ltd. (Beijing, China), with a purity greater than 98%; acyclovir (ACV) was purchased from Beijing Solarbio Biotechnology Co., Ltd. (Beijing, China), with a purity greater than 98%; DMEM culture medium and fetal bovine serum (FBS) were purchased from Gibico Reagents, Inc., USA.
[0029] All animal experiments in this invention were conducted in a biosafety level 2 (BSL-2) laboratory in accordance with the "Guidelines for the Care and Use of Laboratory Animals" (Ministry of Science and Technology of China, 2011); 5-6 week old Babl / c mice were obtained from Qinglongshan Animal Breeding Center (Nanjing, China).
[0030] Example 1: Cytotoxicity test of suicidal saponin A on HSVE susceptible cells (HCE, HconEpic and Primary cornealepithelial cells).
[0031] (1) The three types of cells were respectively loaded with 1×10 4 The cells were seeded into 96-well plates at a density of cells / well and cultured for 24 hours before the experiment began. (2) Remove the cell culture medium from each well, dissolve the blood-breaking saponin A in dimethyl sulfoxide to 20 mM as a reserve, add 100 μl of serially diluted drug DMEM-2% FBS solution to make the final concentrations as follows: 200 μM, 100 μM, 50 μM, 25 μM, 10 μM. At the same time, set up a cell control with 100 μl of blank DMEM-2% FBS. Set up 3 parallel wells for each concentration and put them in a CO2 constant temperature incubator (5% CO2, 37℃) for culture. (3) After culturing for 72 hours, replace the cell culture medium with fresh medium and add 10 μl of CCK-8 cell viability assay reagent to each well. React at room temperature for 2 hours and use an ELISA reader to detect the fluorescence signal of the cells under 450 nm excitation light. Calculate the cell viability according to the kit instructions. (4) Calculate the percentage of cell viability at each concentration based on the measured cell absorbance signal: Cell viability (%) = (Cell uptake value of drug group / Cell uptake value of control group) × 100%; (5) Using Graphpad 8.0 software, a dose-dependent graph of cell viability was plotted with drug concentration on the x-axis and cell viability percentage on the y-axis. The results are as follows: Figure 1 As shown.
[0032] Example 2: The half-maximal effective concentration (EC50) of bleaching saponin A against HSV-1 and HSV-2 in HSVE-susceptible cells (HCE, HconEpic, and Primary corneal epithelial cells). 50 The determination of ).
[0033] (1) The three types of cells were respectively loaded with 1×10 4 The cells were seeded into 96-well plates at a density of cells / well and cultured for 24 hours before the experiment began. (2) Discard the cell culture supernatant and add 100 μl of DMEM-2%FBS solution containing live HSV-1 or HSV-2 virus (MOI=0.1). At the same time, set up a normal cell control group without live virus infection and a virus control group without drug treatment. Set up 3 parallel wells for each concentration and place them in a CO2 constant temperature incubator (5%CO2, 37℃) for infection. (3) Dissolve cyclovir and acyclovir in dimethyl sulfoxide to 20 mM as reserves, and add 50 μl of DMEM-2% FBS solution of graded concentrations to dilute them to final concentrations of 50 μM, 25 μM, 12.5 μM, 6.25 μM, 3.125 μM, 1.5625 μM, 0.78125 μM, and 0.390625 μM, respectively, and then treat the cells. (4) 72 hours after infection, 10 μl of CCK-8 cell viability assay reagent was added to each well and reacted at 37°C for 2 hours. The absorbance signal of the cells under 450 nm excitation light was detected using an enzyme-linked immunosorbent assay reader. (5) Calculate the efficacy of the drug in inhibiting cytopathic effects at various drug concentrations based on cell uptake signals: The efficacy rate (%) of the drug in inhibiting cytopathic effects = (cell absorption value of the drug group - cell absorption value of the virus control group) / (cell absorption value of the cell control group - cell absorption value of the virus control group) × 100%; (6) Using drug concentration as the x-axis and the drug's efficacy in inhibiting cytopathic effects as the y-axis, a dose-dependent curve was plotted using Graphpad 8.0 software, and regression analysis was performed to calculate the half-maximal effective concentration (EC50). 50 ), the result is as follows Figure 2 As shown; (7) Cell states of the normal control group (Control), the virus infection group (HSV-1), and the blood-breaking saponin A administration group (Clin) were recorded by photographing with a Leica ordinary phase-contrast inverted microscope. The results are as follows: Figure 3 As shown.
[0034] Example 3: Detection of the protective effect of bleaching saponin A on HSV-1 ocular inoculation in mice infected with HSVE.
[0035] This experiment was divided into a normal control group (Control), a virus infection group (HSV-1), a virus plus hemolytic saponin A group (HSV-1+Clin), and a virus plus acyclovir group (HSV-1+ACV). The virus plus hemolytic saponin A or acyclovir group was further divided into two administration methods: intraperitoneal injection (IP, 5 or 50 mg / kg) and ocular drops (ED, 1 mg / ml), administered once daily, with 10 mice in each group. Treatment continued for seven days, and observation was maintained for at least ten days, recording mouse weight, survival status, and ocular symptoms. The survival status of the mice is as follows: Figure 4 As shown, the changes in mouse body weight are as follows: Figure 5 As shown in Table 1, the clinical symptoms of the mice were scored, and the scoring criteria are as follows. The experimental results are as follows. Figure 6 As shown.
[0036] in: Control: Babl / c mice around 6 weeks old were injected intraperitoneally with 200 μl of insulin and then instilled with 20 μl of sterile PBS solution into their eyes.
[0037] HSV-1: Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled, resulting in a viral titer of 10. 6 TCID 50 / ml; 2 hours after infection, 200μl was injected intraperitoneally and 20μl of sterile PBS solution was instilled into the eyes.
[0038] HSV-1+Clin (IP, 5 mg / kg): Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled. The viral titer was 10. 6 TCID 50 / ml; 2 hours after infection, 200μl of blood-breaking saponin A in sterile PBS-10%DMSO solution was injected intraperitoneally at a dose of 5mg / kg.
[0039] HSV-1+Clin (ED, 1 mg / ml): Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled, resulting in a viral titer of 10. 6 TCID 50 / ml. Two hours after infection, administer 20 μl of sterile saline solution of blood-breaking saponin A as eye drops at a dose of 1 mg / ml.
[0040] HSV-1+ACV (IP, 50 mg / kg): Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled. The viral titer was 10. 6 TCID 50 / ml. Two hours after infection, 200 μl of acyclovir in sterile PBS-10% DMSO solution was injected intraperitoneally at a dose of 50 mg / kg.
[0041] HSV-1+ACV (ED, 1 mg / ml): Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled. The viral titer was 10. 6 TCID 50 / ml. Two hours after infection, administer 20 μl of sterile saline solution of acyclovir as eye drops at a dose of 1 mg / ml.
[0042] Table 1. Scoring criteria for ocular symptoms in HSV-1 mice injected with HSVE via the eyes.
[0043] Example 4: Detection of the protective effect of suicidal saponin A on HSV-1 inoculated HSVE-infected mice.
[0044] This experiment was divided into a normal control group (Control), a virus infection group (HSV-1), a virus plus hemolytic saponin A group (HSV-1+Clin), and a virus plus acyclovir group (HSV-1+ACV). The virus plus hemolytic saponin A or acyclovir groups were administered via intraperitoneal injection (IP, 5 or 50 mg / kg) once daily, with dosages based on published studies and cell model experiments. Ten mice were in each group. Treatment continued for fourteen days, and mice were observed and recorded for at least twenty-one days, including monitoring their weight, survival status, and ocular symptoms. The survival status of the mice is as follows: Figure 7 As shown, the changes in mouse body weight are as follows: Figure 8 As shown in Table 2, the clinical symptoms of the mice were scored, and the scoring criteria are shown in Table 2. The experimental results are as follows. Figure 9 As shown.
[0045] in: Control: Babl / c mice around 6 weeks old were injected intraperitoneally with 200 μl of sterile PBS solution using an insulin injector.
[0046] HSV-1: Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled, resulting in a viral titer of 10. 6 TCID 50 / ml. Two hours after infection, 200μl of sterile PBS solution was injected intraperitoneally.
[0047] HSV-1+Clin (IP, 5 mg / kg): Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled. The viral titer was 10. 6 TCID 50 / ml. Two hours after infection, 200μl of blood-breaking saponin A in sterile PBS-10% DMSO solution was injected intraperitoneally at a dose of 5mg / kg.
[0048] HSV-1+ACV (IP, 50 mg / kg): Babl / c mice around 6 weeks old were infected with the virus. The cornea was gently scraped with an insulin syringe and 10 μL of HSV-1 solution was instilled. The viral titer was 10. 6 TCID 50 / ml. Two hours after infection, 200 μl of acyclovir in sterile PBS-10% DMSO solution was injected intraperitoneally at a dose of 50 mg / kg.
[0049] Table 2. Symptom scoring criteria for HSV-1 intranasal inoculation with HSVE mice
[0050] Example 5: Duanxueliu saponin A is mainly extracted from the Chinese medicinal herb Duanxueliu. This application example is used to determine the anti-HSV-1 activity of 15 main components of the Chinese medicinal herb Duanxueliu (namely luteolin, apigenin, isosalicylic acid, Duanxueliu saponin A, lemon balm glycoside, naringenin, rutin, apigenin-7-O-glucuronide, hesperidin, hesperidin, gallic acid, quercetin, safflower glycoside, saikosaponin, and rosmarinic acid) in human corneal epithelial cells (HCE).
[0051] (1) The cells were loaded with 1×10 4 The cells were seeded into 96-well plates at a density of cells / well and cultured for 24 hours before the experiment began. (2) Discard the cell culture supernatant and add 100 μl of DMEM-2% FBS solution containing live HSV-1 virus (MOI=0.1). At the same time, set up a normal cell control group without live virus infection and a virus control group without active ingredient treatment. Set up 3 parallel wells for each concentration and place them in a CO2 constant temperature incubator for infection under the conditions of 5% CO2 and 37℃. (3) Subsequently, 50 μl of DMEM-2%FBS solution, which brings the final concentration to 20 or 10 μM, was added to treat the cells. (4) 72 hours after infection, add 10 μl of CCK-8 cell viability assay reagent to each well, react at 37°C for 2 hours, and use an enzyme-linked immunosorbent assay reader to detect the cell absorbance signal under 450 nm excitation light. (5) Calculate the efficacy rate of the active ingredient in inhibiting cytopathic effects at various drug concentrations based on cell uptake signals: The efficacy rate (%) of the active ingredient in inhibiting cytopathic effects = (Cell uptake value of active ingredient group / Cell uptake value of control group) × 100%; (6) Using the active ingredient number as the x-axis and the effective rate of the active ingredient in inhibiting cytopathic effects as the y-axis, a bar chart of antiviral activity was drawn using Graphpad 8.0 software. The experimental results are as follows: Figure 10 As shown.
[0052] Example 6: As a possible implementation method, this example provides a pharmaceutically acceptable salt of cyclophosphamide A, wherein the pharmaceutically acceptable salt of cyclophosphamide A is a pharmaceutically acceptable sodium salt of cyclophosphamide A. When applied to the experiments in Examples 1 to 4, the effect is comparable to that of cyclophosphamide A.
[0053] Conclusion: Tests conducted in Examples 1-4 revealed that in HSVE-susceptible cells (HCE, HconEpic, and Primarycorneal epithelial cells), the half-maximal effective concentration (EC50) of glycoside A for HSV-1 was [value missing]. 50 The effective concentration range was 5.286–8.293 μM, while the half-maximum effective concentration (EC50) for HSV-2 was 5.286–8.293 μM. 50The concentration range was only 19.54–24.73 μM, indicating that its inhibitory effect on HSV-1 was superior to that on HSV-2. In two mouse models of HSVE induced by HSV-1 infection—ocular and nasal inoculation—Duanxueliu saponin A effectively improved the clinical symptoms and increased the survival rate of mice. Data from Example 5 show that among the various main components of the traditional Chinese medicine Duanxueliu, Duanxueliu saponin A exhibited significantly better inhibitory effects on HSV-1 infection in HSVE-susceptible cells than other components, providing a data basis for the feasibility of using Duanxueliu as a therapeutic agent for HSV-1-induced HSVE.
[0054] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.
[0055] Finally, it should be noted that the above descriptions are merely preferred embodiments of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. The use of a blood-breaking saponin A or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating viral eye diseases, characterized in that: Viral eye disease is a herpes simplex virus eye disease induced by herpes simplex virus type I; the molecular formula of blood-breaking saponin A is C. 48 H 78 O 19 The structural formula is: ; The glycoside A of the blood-breaking saponin is extracted from the Chinese medicinal herb blood-breaking saponin.
2. The use of the blood-breaking saponin A or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a drug for treating viral eye diseases, characterized in that: The median effective concentration (EC50) of herpes simplex virus type I of bismuth substituent A or its pharmaceutically acceptable salt. 50 The range is 5.286~8.293μM.
3. The use of the blood-breaking saponin A or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a drug for treating viral eye diseases, characterized in that: The medication is either an injection or eye drops.
4. The use of a blood-breaking saponin A or a pharmaceutically acceptable salt thereof according to claim 3 in the preparation of a drug for treating viral eye diseases, characterized in that: The injection is administered via intraperitoneal injection, and the dosage of thrombolytic saponin A or its pharmaceutically acceptable salt is 5 mg / kg.
5. The use of a blood-breaking saponin A or a pharmaceutically acceptable salt thereof according to claim 3 in the preparation of a drug for treating viral eye diseases, characterized in that: The eye drops are administered by dropping into the eye, with a single dose of 20 μl. The concentration of blood flow interrupting saponin A or its pharmaceutically acceptable salt in the eye drops is 1 mg / mL.
